A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC) — Stella
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(107 sites)
United States
Highlands Oncology Group., Springdale, Arkansas
Kaiser Permanente - Baldwin Park, Baldwin Park, California
City of Hope Cancer Center, Duarte, California
Kaiser Permanente - Los Angeles (N. Vermont), Los Angeles, California
Kaiser Permanente - Riverside, Riverside, California
University of California San Francisco, San Francisco, California
Yale Cancer Center, New Haven, Connecticut
Georgetown University Medical Center Lombardi Cancer Center, Washington D.C., District of Columbia
Norton Cancer Institute, Louisville, Kentucky
Henry Ford Health System, Detroit, Michigan
Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, New Jersey
MSK Monmouth, Middletown, New Jersey
MSK Bergen, Montvale, New Jersey
Argentina
Instituto Alexander Fleming, Buenos Aires
Hospital Britanico, Buenos Aires
Hospital Italiano, Ciudad Autonoma Buenos Aires
Australia
Lyell McEwin Hospital, Elizabeth Vale, South Australia
Box Hill Hospital, Box Hill, Victoria
Sunshine Hospital, St Albans, Victoria
Belgium
UZ Gent, Ghent
AZ Groeninge, Kortrijk
UZ Leuven Gasthuisberg, Leuven
Clinique Ste-Elisabeth, Namur
Brazil
Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul